Pregabalin: a new approach to treatment of the dysautonomic crisis.
Nausea and dysautonomic crises severely limit function and quality of life for a large number of individuals with familial dysautonomia. We treated a small cohort of 15 patients with familial dysautonomia who suffered frequent dysautonomic crises with pregabalin. Nausea and overt crises markedly decreased in 13 (87%) of these patients and the overall assessments of benefit were extremely favorable, suggesting that pregabalin may be a potentially useful therapeutic agent for this disorder.
Axelrod
Felicia B
FB
Department of Pediatrics, New York University School of Medicine, New York, New York 10016, USA. felicia.axelrod@nyumc.org
Berlin
Dena
D
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000235:genetics; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004402:Dysautonomia, Familial / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D000069583:Pregabalin; D035602:Transcriptional Elongation Factors; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000927:Anticonvulsants; D002352:Carrier Proteins; C114720:Elp1 protein, human; D035602:Transcriptional Elongation Factors; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid